RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
June 18, 2019
RegMed Investors’ (RMi) closing bell: riding the sector trend as the market surges
June 15, 2019
RegMed Investors’ (RMi) closing bell: alchemy in reverse
June 13, 2019
RegMed Investors’ (RMi) closing bell: upward motion
June 12, 2019
RegMed Investors’ (RMi) closing bell: a return from the bottom
June 11, 2019
RegMed Investors’ (RMi) closing bell: risk has never stopped being a four letter expletive
June 10, 2019
RegMed Investors’ (RMi) closing bell: take a pew for news of share pricing exhibiting a risk on/off status
June 7, 2019
RegMed Investors’ (RMi) closing bell: oversold sensitivity enhances sector upside
June 6, 2019
RegMed Investors’ (RMi) closing bell: it ain’t easy to make a buck in this sector lately unless you're short
June 5, 2019
RegMed Investors’ (RMi) closing bell: did or will the dead cat bounce?
June 4, 2019
RegMed Investors’ (RMi) closing bell: a rally to the close
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.